TickerFactsScreenerDevelopers

HALOZYME THERAPEUTICS, INC. (HALO) — Cash & Equivalents

Annual figures by fiscal year, from SEC filings.

2008: $63.72M2009: $67.46M2010: $82.76M2011: $52.38M2012: $99.50M2013: $27.36M2014: $61.39M2015: $43.29M2016: $66.76M2017: $168.74M2018: $57.94M2019: $120.18M2020: $147.70M2021: $118.72M2022: $234.19M2023: $118.37M2024: $115.85M2025: $133.82M$133.82M
2008Cash & Equivalents (USD)2025
Fiscal YearCash & EquivalentsChange YoY
2025$133.82M+15.5%
2024$115.85M-2.1%
2023$118.37M-49.5%
2022$234.19M+97.3%
2021$118.72M-19.6%
2020$147.70M+22.9%
2019$120.18M+107.4%
2018$57.94M-65.7%
2017$168.74M+152.7%
2016$66.76M+54.2%
2015$43.29M-29.5%
2014$61.39M+124.4%
2013$27.36M-72.5%
2012$99.50M+90.0%
2011$52.38M-36.7%
2010$82.76M+22.7%
2009$67.46M+5.9%
2008$63.72M—